These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27892684)

  • 41. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
    Vardeny O; Tacheny T; Solomon SD
    Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
    Docherty KF; McMurray JJV
    Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
    Andersen MB; Simonsen U; Wehland M; Pietsch J; Grimm D
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):14-22. PubMed ID: 26280447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies.
    Tummala R; Bhadra R; Gupta A; Ghosh RK
    J Cardiovasc Pharmacol; 2016 Sep; 68(3):183-90. PubMed ID: 27092662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
    Liu Y; Fan Y; Li J; Chen M; Chen A; Yang D; Guan X; Cao Y
    Biomed Pharmacother; 2021 Jan; 133():110824. PubMed ID: 33378988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
    Voors AA; Gori M; Liu LC; Claggett B; Zile MR; Pieske B; McMurray JJ; Packer M; Shi V; Lefkowitz MP; Solomon SD;
    Eur J Heart Fail; 2015 May; 17(5):510-7. PubMed ID: 25657064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Neprilysin inhibition and chronic kidney disease].
    Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A
    G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurohumoral Activation in Heart Failure.
    Manolis AA; Manolis TA; Manolis AS
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
    Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
    Gan L; Langenickel T; Petruck J; Kode K; Rajman I; Chandra P; Zhou W; Rebello S; Sunkara G
    J Clin Pharmacol; 2016 Jan; 56(1):78-86. PubMed ID: 26073563
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ARNIs: balancing "the good and the bad" of neuroendocrine response to HF.
    Ferrari R; Cardoso J; Fonseca MC; Aguiar C; Moreira JI; Fucili A; Rapezzi C;
    Clin Res Cardiol; 2020 May; 109(5):599-610. PubMed ID: 31531687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.
    Volpe M; Tocci G; Battistoni A; Rubattu S
    High Blood Press Cardiovasc Prev; 2015 Sep; 22(3):241-6. PubMed ID: 26100410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?
    Katsi V; Skalis G; Pavlidis AN; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):260-4. PubMed ID: 27532450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice.
    Ge Q; Zhao L; Liu C; Ren X; Yu YH; Pan C; Hu Z
    Biomed Res Int; 2020; 2020():7256862. PubMed ID: 32420365
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [First Experience of Clinical Application of LCZ696--an AT1-angiotensin Receptors and Neprilysin Inhibitor--in Patients With Chronic Heart Failure and Reduced Ejection Fraction].
    Kobalava ZhD; Pavlikova EP; Averkov OA; Merai I; Babaeva LA; Amirbegishvili IM; Kotovskaya YV; Moisfev VS
    Kardiologiia; 2015; 55(7):14-25. PubMed ID: 26688921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
    Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
    Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.